In PCs, insensitiveness to the immune checkpoint blockade may be due to various mechanisms, including modifications of drug targets, activation of pro-survival pathways, disability of apoptosis machinery, relatively low tumor mutation burden and/or scant intratumoral CD8+ T-cell infiltrate. This evidence concerns the gene CD8A and neoplasm.